ESC 365 - Efficacy and safety of prolonged edoxaban treatment for gastrointestinal cancer patients with isolated distal deep vein thrombosis: insight from the ONCO DVT study

ESC2025 Premium Access

Efficacy and safety of prolonged edoxaban treatment for gastrointestinal cancer patients with isolated distal deep vein thrombosis: insight from the ONCO DVT study

Session: Refining risk scores in cardio-oncology

Topic: Cardio-Oncology

Speaker: Doctor Y. Yamashita (Kyoto, JP)

Event: ESC Congress 2025

Congress Presentation

Add to my library

About the speaker

Doctor Yugo Yamashita

Kyoto University Graduate School of Medicine, Kyoto (Japan)

2 presentations

1 follower

5 more presentations in this session

Key immune related genes and potential therapeutic targets in immune checkpoint inhibitor associated myocarditis: a new fing

Speaker: Doctor J. Zhang (Suzhou, CN)

Predictive factors and baseline risk stratification for CAR-T cell therapy-related cardiovascular toxicity

Speaker: Professor D. Farmakis (Athens, GR)

Cardiovascular disease is a significant contributor to the incidence of cancer, second-primary cancer, and cancer-related hospitalization

Speaker: Mr T. Caller (Tel Aviv, IL)

A novel machine learning-based adverse cardiovascular events risk score for cancer patients treated with immune checkpoint inhibitors

Speaker: Mr J. Cross (New Haven, US)

Myocardial fibrosis identification in patients with anthracycline-induced cardiotoxicity: a biomarkers and cardiac magnetic resonance correlation

Speaker: Doctor R. Maragna (Milan, IT)

Access the full session

Refining risk scores in cardio-oncology

Speakers: Doctor Y. Yamashita, Doctor J. Zhang, Professor D. Farmakis, Mr T. Caller, Mr J. Cross...

About the event

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress

ESC 365 is supported by

bristol-myers-squibb

Explore sponsored resources

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources